Intranasal Drug Delivery Devices Market

Global Intranasal Drug Delivery Devices Market

  • HC-4227
  • 4.4 Rating
  • 289 Pages
  • 20-01-2022
  • 78 Reviews
  • PDF Excel PPT
raksha

Author:

Raksha Sharma

Vineet

Fact-checked by:

Vineet Pandey

Shreyas

Editor:

Shreyas Tandon

Intranasal Drug Delivery Devices Market Outlook

The global intranasal drug delivery devices market was valued at USD 4,061.4 Mn in 2020 and is expected to reach USD 6,601.7 Mn by 2028, expanding at a CAGR of 6.5% during the forecast period. Nasal administration has been used for therapeutic purposes for centuries. The respiratory tract is a primary contact area for the environment and it represents a gateway for potential treatments and infectious particles such as viruses & bacteria. Intranasal administration is a non-invasive drug route of administration, widely used for the local treatment of nasal polyposis or rhinitis.

In order to obtain effective and safe intranasal pharmaceutical products, a large number of strategies is applied to overcome nasal release barriers. In the design of a nasal product, three main cooperative entities must be considered: the administration device, the drug, and the delivery carrier. Nasal drug administration has been used as an alternative route for the systemic availability of drugs restricted to intravenous administration.

This is attributed to the large surface area, porous endothelial membrane, high total blood flow, avoidance of first-pass metabolism, and ready accessibility. The nasal administration of drugs, including numerous compounds, peptide and protein drugs, for systemic medication has been widely investigated in recent years. Drugs are cleared rapidly from the nasal cavity after intranasal administration, resulting in rapid systemic drug absorption.

 Intranasal Drug Delivery Devices Market Market Outlook

Scope of Intranasal Drug Delivery Devices Market Report

The report on the global Intranasal Drug Delivery Devices Market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
 

Attributes

Details

Report Title

Intranasal Drug Delivery Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Product (Powder Delivery Device, Liquid Delivery Device, Pressurized Metered-dose Inhalers, and Others), Dosage (Unit-dose and Multi-dose) Application (Respiratory Disorders, Neurological Disorder, Vaccination, Pain Management and Others), End-user (Personal Use, Hospitals/Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered

Teleflex Incorporated, AptarGroup, Inc., Johnson & Johnson, BD, Teva Pharmaceutical Industries Ltd, Vectura Group plc, Recipharm AB, H&T Presspart Manufacturing Ltd, Nemera Development S.A., OptiNose Inc, and Others.

Intranasal Drug Delivery Devices Market Dynamics

Increasing Prevalence of Chronic Disease

Demand for nasal sprays is growing, owing to the increasing prevalence of chronic diseases, such as cardiovascular diseases (CVDs), nasal congestion, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease (COPD), and diabetes. This is expected to propel the intranasal drug delivery devices market during the forecast period.

Topical forms of medical therapy represent an attractive alternative for the administration of drugs into the paranasal sinuses and nasal cavity. The increasing incidence of chronic diseases is projected to contribute to the expansion of the intranasal drug delivery devices market over the coming years.

Introduction of Off-patent Drugs for Respiratory Care to Reconcile the Supply of MDIs and DPIs

The expiration of the patent for branded inhaled drugs and increasing pressure on the healthcare budget are leading to the development of generic inhaled drugs. As the cost of treating asthma and COPD decreases, awareness and the adoption of MDI & DPI are likely to increase among patients. Companies are focusing on the development of low-cost drugs to provide cost-effective treatment.

For instance, in February 2019, the US Food and Drug Administration (FDA) approved Mylan’s generic version of Advair Diskus of GlaxoSmithKline. The generic drug (Wixela Inhub) is intended for the treatment of asthma and COPD patients and was launched at a lower price than the brand. Additionally, increased patient awareness of the benefits of using MDI and DPI are expected to propel the market over the coming years.

Restraints

Rising Complications associated with the overuse of nasal sprays

Sprays are easy to access for patients, hence most people mistakenly presume that nasal sprays are safe to use and are unaware of the potential addiction or possible side effects. Rhinitis Medicamentosa (RM) refers to the nasal inflammation caused by the use of medications. It is common for patients who regularly use nasal sprays to abuse the drug.

Continuous use of nasal sprays leads to down-regulation of the receptors on the blood vessel in the nose, which methat the number of receptors decreases, and when the user stops taking the drug, a rebound effect of nasal inflammation occurs. Atrophy of the nasal mucosa is a common drawback associated with rhinitis medicamentosa. This includes scars of the nose coating, which causes symptoms such as bleeding, dry nose, and irritation.

Difficulty in delivering the drug to the olfactory region of the human nasal cavity

Drug delivery devices have been found to play an important role in ensuring that all of the drugs are delivered to the target site in the nasal cavity. It is difficult to accurately deliver the drug to the olfactory region of the human nasal cavity, as this region is located high in the nasal cavity, above the upper concha. This area is exposed to a low volume of air entering the nasal cavity and leads to low doses of the drug reaching the olfactory region. This in turn, is expected to impede the growth of the intranasal drug delivery devices market during the forecast period.

Opportunity

Increasing R&D Activities

Innovative strategic approaches to design efficient nasal delivery systems for specific drugs are currently in various stages of research and development. These include the design of barriers that prevent the degradation of drugs by mucosal enzymes, sophisticated devices for targeted drug delivery to the brain, new and improved nasal delivery technologies, and the modulation of physicochemical properties of the vectors. This in turn, is anticipated to provide various lucrative growth opportunities during the forecast period.

 Intranasal Drug Delivery Devices Market Segmental Outlook

The intranasal drug delivery devices market is segmented into products, dosage, applications, end-users, distribution channels, and regions.

On the basis of products, the global intranasal drug delivery devices market is segmented into powder delivery device, liquid delivery device, pressurized metered-dose inhalers, and others. The liquid delivery device segment held a significant market share and is anticipated to grow in the coming years. Liquid delivery devices are considered convenient, particularly for topical indications where humidification counteracts the dryness and crusting often accompanying chronic nasal diseases.

 Intranasal Drug Delivery Devices Market Product

Based on dosage, the global intranasal drug delivery devices market is segmented into unit-dose and multi-dose. The unit-dose segment held a significant market share and is anticipated to grow in the coming years. A unit-dose device is for single-use, pre-filled, already-assembled, disposable products such as IMITREX (sumatriptan nasal spray) and NARCAN (naloxone nasal spray). It is ideal for urgent treatments.


In terms of applications, the global intranasal drug delivery devices market is segmented into respiratory disorders, neurological disorders, vaccination, pain management, and others. The increasing prevalence of respiratory disorders such as asthma and COPD among people is expected to propel the global intranasal drug delivery devices market in the coming years.

 Intranasal Drug Delivery Devices Market Application
On the basis of end-users, the global intranasal drug delivery devices market is segmented into personal use, hospitals/clinics, and others. The personal use segment is expected to hold a significant market share during the forecast period, owing to increasing patient preference for self-administrated drugs and the growing usage of nasal sprays and powders that are easily administered by patients. Furthermore, the self-administration of drugs in home care settings helps patients save money and time, which in turn, brings down healthcare costs incurred by the patient.

Based on distribution channels, the global intranasal drug delivery devices market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held a significant market share and is anticipated to grow in the coming years, owing to increasing focus on positive medical outcomes, patient awareness, and self-administration.

 Intranasal Drug Delivery Devices Market Regional Outlook

On the basis of regions, the global intranasal drug delivery devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is projected to expand at a significant CAGR during the forecast period, owing to increasing government (U.S. FDA) approval for the use of the intranasal drug delivery devices such as nasal sprays and nasal powder.

The market in Europe is expected to grow at a rapid pace during the forecast period, due to the presence of large number of players in the region. The market in Asia Pacific is projected to hold considerable market share during the forecast period, owing to increasing R&D activities in countries such as China.

 Intranasal Drug Delivery Devices Market Region

Key Benefits for Industry Participants & Stakeholders

  • In-depth Analysis of the Global Intranasal Drug Delivery Devices market
  • Historical, Current and Projected Market Size in terms of Value and Volume
  • Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
  • Industry Drivers, Restraints and Opportunities Covered in the Study
  • Recent Industry Trends and Developments
  • Competitive Landscape & Strategies of Key Players
  • Neutral Perspective on Global Intranasal Drug Delivery Devices Market Performance

Segments

By Product

  • Powder Delivery Device
  • Liquid Delivery Device
  • Pressurized Metered-dose Inhalers
  • Others

By Dosage

  • Unit-dose
  • Multi-dose

By Application

  • Respiratory Disorders
  • Neurological Disorder
  • Vaccination
  • Pain Management
  • Others

By End-user

  • Personal Use
  • Hospitals/Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key Market Players Profiled in the Report

  • Teleflex Incorporated
  • AptarGroup, Inc.
  • Johnson & Johnson
  • BD
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group plc
  • Recipharm AB
  • H&T Presspart Manufacturing Ltd
  • Nemera Development S.A.
  • OptiNose Inc
  • Others

Competitive Landscape

  • Top players in the market include Johnson & Johnson, BD, Teva Pharmaceutical Industries Ltd, Nemera Development S.A., AptarGroup, Inc., and Recipharm AB Limited these companies are considered as key manufacturers of piezoelectric element based on their revenue, product offerings, regional presence, and supply chain management system.
  • The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Intranasal Drug Delivery Devices market.

 Intranasal Drug Delivery Devices Market Key Players

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Intranasal Drug Delivery Devices Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Intranasal Drug Delivery Devices Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Intranasal Drug Delivery Devices Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Intranasal Drug Delivery Devices Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Intranasal Drug Delivery Devices Market Size & Forecast, 2018-2028
      4.5.1 Intranasal Drug Delivery Devices Market Size and Y-o-Y Growth
      4.5.2 Intranasal Drug Delivery Devices Market Absolute $ Opportunity
   4.6 Suppliers and their Offerings Outlook
   4.7 Preservative Free Pump Technology Suppliers Overview
   4.8 Unidose and Bidose Intranasal Delivery Systems Suppliers Outlook
   4.9 Pipeline Analysis
   4.10 Intranasal Nebuliser Systems Outlook
Chapter 5 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By Product
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Product
      5.1.2 Basis Point Share (BPS) Analysis By Product
      5.1.3 Absolute $ Opportunity Assessment By Product
   5.2 Intranasal Drug Delivery Devices Market Size Forecast By Product
      5.2.1 Powder Delivery Devic
      5.2.2 Liquid Delivery Device
      5.2.3 Pressurized Metered-dose
      5.2.4 Inhalers
      5.2.5 Others
   5.3 Market Attractiveness Analysis By Product
Chapter 6 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By Dosage
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Dosage
      6.1.2 Basis Point Share (BPS) Analysis By Dosage
      6.1.3 Absolute $ Opportunity Assessment By Dosage
   6.2 Intranasal Drug Delivery Devices Market Size Forecast By Dosage
      6.2.1 Unit-dose
      6.2.2 Multi-dose
   6.3 Market Attractiveness Analysis By Dosage
Chapter 7 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By Application
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Application
      7.1.2 Basis Point Share (BPS) Analysis By Application
      7.1.3 Absolute $ Opportunity Assessment By Application
   7.2 Intranasal Drug Delivery Devices Market Size Forecast By Application
      7.2.1 Respiratory Disorders
      7.2.2 Neurological Disorder
      7.2.3 Vaccination
      7.2.4 Pain Management
      7.2.5 Others
   7.3 Market Attractiveness Analysis By Application
Chapter 8 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By End-user
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities By End-user
      8.1.2 Basis Point Share (BPS) Analysis By End-user
      8.1.3 Absolute $ Opportunity Assessment By End-user
   8.2 Intranasal Drug Delivery Devices Market Size Forecast By End-user
      8.2.1 Personal Use
      8.2.2 Hospitals/Clinics
      8.2.3 Others
   8.3 Market Attractiveness Analysis By End-user
Chapter 9 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By Distribution Channel
   9.1 Introduction
      9.1.1 Key Market Trends & Growth Opportunities By Distribution Channel
      9.1.2 Basis Point Share (BPS) Analysis By Distribution Channel
      9.1.3 Absolute $ Opportunity Assessment By Distribution Channel
   9.2 Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
      9.2.1 Hospital Pharmacies
      9.2.2 Retail Pharmacies
      9.2.3 Online Pharmacies
   9.3 Market Attractiveness Analysis By Distribution Channel

Chapter 10 Global Intranasal Drug Delivery Devices Market Analysis and Forecast by Region
   10.1 Introduction
      10.1.1 Key Market Trends & Growth Opportunities by Region
      10.1.2 Basis Point Share (BPS) Analysis by Region
      10.1.3 Absolute $ Opportunity Assessment by Region
   10.2 Intranasal Drug Delivery Devices Market Size Forecast by Region
      10.2.1 North America
      10.2.2 Europe
      10.2.3 Asia Pacific
      10.2.4 Latin America
      10.2.5 Middle East & Africa (MEA)
   10.3 Market Attractiveness Analysis by Region
Chapter 11 Coronavirus Disease (COVID-19) Impact
   11.1 Introduction
   11.2 Current & Future Impact Analysis
   11.3 Economic Impact Analysis
   11.4 Government Policies
   11.5 Investment Scenario
Chapter 12 North America Intranasal Drug Delivery Devices Analysis and Forecast
   12.1 Introduction
   12.2 North America Intranasal Drug Delivery Devices Market Size Forecast by Country
      12.2.1 U.S.
      12.2.2 Canada
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 North America Intranasal Drug Delivery Devices Market Size Forecast By Product
      12.6.1 Powder Delivery Devic
      12.6.2 Liquid Delivery Device
      12.6.3 Pressurized Metered-dose
      12.6.4 Inhalers
      12.6.5 Others
   12.7 Basis Point Share (BPS) Analysis By Product
   12.8 Absolute $ Opportunity Assessment By Product
   12.9 Market Attractiveness Analysis By Product
   12.10 North America Intranasal Drug Delivery Devices Market Size Forecast By Dosage
      12.10.1 Unit-dose
      12.10.2 Multi-dose
   12.11 Basis Point Share (BPS) Analysis By Dosage
   12.12 Absolute $ Opportunity Assessment By Dosage
   12.13 Market Attractiveness Analysis By Dosage
   12.14 North America Intranasal Drug Delivery Devices Market Size Forecast By Application
      12.14.1 Respiratory Disorders
      12.14.2 Neurological Disorder
      12.14.3 Vaccination
      12.14.4 Pain Management
      12.14.5 Others
   12.15 Basis Point Share (BPS) Analysis By Application
   12.16 Absolute $ Opportunity Assessment By Application
   12.17 Market Attractiveness Analysis By Application
   12.18 North America Intranasal Drug Delivery Devices Market Size Forecast By End-user
      12.18.1 Personal Use
      12.18.2 Hospitals/Clinics
      12.18.3 Others
   12.19 Basis Point Share (BPS) Analysis By End-user
   12.20 Absolute $ Opportunity Assessment By End-user
   12.21 Market Attractiveness Analysis By End-user
   12.22 North America Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
      12.22.1 Hospital Pharmacies
      12.22.2 Retail Pharmacies
      12.22.3 Online Pharmacies
   12.23 Basis Point Share (BPS) Analysis By Distribution Channel
   12.24 Absolute $ Opportunity Assessment By Distribution Channel
   12.25 Market Attractiveness Analysis By Distribution Channel

Chapter 13 Europe Intranasal Drug Delivery Devices Analysis and Forecast
   13.1 Introduction
   13.2 Europe Intranasal Drug Delivery Devices Market Size Forecast by Country
      13.2.1 Germany
      13.2.2 France
      13.2.3 Italy
      13.2.4 U.K.
      13.2.5 Spain
      13.2.6 Russia
      13.2.7 Rest of Europe
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Europe Intranasal Drug Delivery Devices Market Size Forecast By Product
      13.6.1 Powder Delivery Devic
      13.6.2 Liquid Delivery Device
      13.6.3 Pressurized Metered-dose
      13.6.4 Inhalers
      13.6.5 Others
   13.7 Basis Point Share (BPS) Analysis By Product
   13.8 Absolute $ Opportunity Assessment By Product
   13.9 Market Attractiveness Analysis By Product
   13.10 Europe Intranasal Drug Delivery Devices Market Size Forecast By Dosage
      13.10.1 Unit-dose
      13.10.2 Multi-dose
   13.11 Basis Point Share (BPS) Analysis By Dosage
   13.12 Absolute $ Opportunity Assessment By Dosage
   13.13 Market Attractiveness Analysis By Dosage
   13.14 Europe Intranasal Drug Delivery Devices Market Size Forecast By Application
      13.14.1 Respiratory Disorders
      13.14.2 Neurological Disorder
      13.14.3 Vaccination
      13.14.4 Pain Management
      13.14.5 Others
   13.15 Basis Point Share (BPS) Analysis By Application
   13.16 Absolute $ Opportunity Assessment By Application
   13.17 Market Attractiveness Analysis By Application
   13.18 Europe Intranasal Drug Delivery Devices Market Size Forecast By End-user
      13.18.1 Personal Use
      13.18.2 Hospitals/Clinics
      13.18.3 Others
   13.19 Basis Point Share (BPS) Analysis By End-user
   13.20 Absolute $ Opportunity Assessment By End-user
   13.21 Market Attractiveness Analysis By End-user
   13.22 Europe Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
      13.22.1 Hospital Pharmacies
      13.22.2 Retail Pharmacies
      13.22.3 Online Pharmacies
   13.23 Basis Point Share (BPS) Analysis By Distribution Channel
   13.24 Absolute $ Opportunity Assessment By Distribution Channel
   13.25 Market Attractiveness Analysis By Distribution Channel
Chapter 14 Asia Pacific Intranasal Drug Delivery Devices Analysis and Forecast
   14.1 Introduction
   14.2 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast by Country
      14.2.1 China
      14.2.2 Japan
      14.2.3 South Korea
      14.2.4 India
      14.2.5 Australia
      14.2.6 South East Asia (SEA)
      14.2.7 Rest of Asia Pacific (APAC)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By Product
      14.6.1 Powder Delivery Devic
      14.6.2 Liquid Delivery Device
      14.6.3 Pressurized Metered-dose
      14.6.4 Inhalers
      14.6.5 Others
   14.7 Basis Point Share (BPS) Analysis By Product
   14.8 Absolute $ Opportunity Assessment By Product
   14.9 Market Attractiveness Analysis By Product
   14.10 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By Dosage
      14.10.1 Unit-dose
      14.10.2 Multi-dose
   14.11 Basis Point Share (BPS) Analysis By Dosage
   14.12 Absolute $ Opportunity Assessment By Dosage
   14.13 Market Attractiveness Analysis By Dosage
   14.14 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By Application
      14.14.1 Respiratory Disorders
      14.14.2 Neurological Disorder
      14.14.3 Vaccination
      14.14.4 Pain Management
      14.14.5 Others
   14.15 Basis Point Share (BPS) Analysis By Application
   14.16 Absolute $ Opportunity Assessment By Application
   14.17 Market Attractiveness Analysis By Application
   14.18 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By End-user
      14.18.1 Personal Use
      14.18.2 Hospitals/Clinics
      14.18.3 Others
   14.19 Basis Point Share (BPS) Analysis By End-user
   14.20 Absolute $ Opportunity Assessment By End-user
   14.21 Market Attractiveness Analysis By End-user
   14.22 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
      14.22.1 Hospital Pharmacies
      14.22.2 Retail Pharmacies
      14.22.3 Online Pharmacies
   14.23 Basis Point Share (BPS) Analysis By Distribution Channel
   14.24 Absolute $ Opportunity Assessment By Distribution Channel
   14.25 Market Attractiveness Analysis By Distribution Channel
Chapter 15 Latin America Intranasal Drug Delivery Devices Analysis and Forecast
   15.1 Introduction
   15.2 Latin America Intranasal Drug Delivery Devices Market Size Forecast by Country
      15.2.1 Brazil
      15.2.2 Mexico
      15.2.3 Rest of Latin America (LATAM)
   15.3 Basis Point Share (BPS) Analysis by Country
   15.4 Absolute $ Opportunity Assessment by Country
   15.5 Market Attractiveness Analysis by Country
   15.6 Latin America Intranasal Drug Delivery Devices Market Size Forecast By Product
      15.6.1 Powder Delivery Devic
      15.6.2 Liquid Delivery Device
      15.6.3 Pressurized Metered-dose
      15.6.4 Inhalers
      15.6.5 Others
   15.7 Basis Point Share (BPS) Analysis By Product
   15.8 Absolute $ Opportunity Assessment By Product
   15.9 Market Attractiveness Analysis By Product
   15.10 Latin America Intranasal Drug Delivery Devices Market Size Forecast By Dosage
      15.10.1 Unit-dose
      15.10.2 Multi-dose
   15.11 Basis Point Share (BPS) Analysis By Dosage
   15.12 Absolute $ Opportunity Assessment By Dosage
   15.13 Market Attractiveness Analysis By Dosage
   15.14 Latin America Intranasal Drug Delivery Devices Market Size Forecast By Application
      15.14.1 Respiratory Disorders
      15.14.2 Neurological Disorder
      15.14.3 Vaccination
      15.14.4 Pain Management
      15.14.5 Others
   15.15 Basis Point Share (BPS) Analysis By Application
   15.16 Absolute $ Opportunity Assessment By Application
   15.17 Market Attractiveness Analysis By Application
   15.18 Latin America Intranasal Drug Delivery Devices Market Size Forecast By End-user
      15.18.1 Personal Use
      15.18.2 Hospitals/Clinics
      15.18.3 Others
   15.19 Basis Point Share (BPS) Analysis By End-user
   15.20 Absolute $ Opportunity Assessment By End-user
   15.21 Market Attractiveness Analysis By End-user
   15.22 Latin America Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
      15.22.1 Hospital Pharmacies
      15.22.2 Retail Pharmacies
      15.22.3 Online Pharmacies
   15.23 Basis Point Share (BPS) Analysis By Distribution Channel
   15.24 Absolute $ Opportunity Assessment By Distribution Channel
   15.25 Market Attractiveness Analysis By Distribution Channel
Chapter 16 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Analysis and Forecast
   16.1 Introduction
   16.2 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast by Country
      16.2.1 Saudi Arabia
      16.2.2 South Africa
      16.2.3 UAE
      16.2.4 Rest of Middle East & Africa (MEA)
   16.3 Basis Point Share (BPS) Analysis by Country
   16.4 Absolute $ Opportunity Assessment by Country
   16.5 Market Attractiveness Analysis by Country
   16.6 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By Product
      16.6.1 Powder Delivery Devic
      16.6.2 Liquid Delivery Device
      16.6.3 Pressurized Metered-dose
      16.6.4 Inhalers
      16.6.5 Others
   16.7 Basis Point Share (BPS) Analysis By Product
   16.8 Absolute $ Opportunity Assessment By Product
   16.9 Market Attractiveness Analysis By Product
   16.10 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By Dosage
      16.10.1 Unit-dose
      16.10.2 Multi-dose
   16.11 Basis Point Share (BPS) Analysis By Dosage
   16.12 Absolute $ Opportunity Assessment By Dosage
   16.13 Market Attractiveness Analysis By Dosage
   16.14 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By Application
      16.14.1 Respiratory Disorders
      16.14.2 Neurological Disorder
      16.14.3 Vaccination
      16.14.4 Pain Management
      16.14.5 Others
   16.15 Basis Point Share (BPS) Analysis By Application
   16.16 Absolute $ Opportunity Assessment By Application
   16.17 Market Attractiveness Analysis By Application
   16.18 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By End-user
      16.18.1 Personal Use
      16.18.2 Hospitals/Clinics
      16.18.3 Others
   16.19 Basis Point Share (BPS) Analysis By End-user
   16.20 Absolute $ Opportunity Assessment By End-user
   16.21 Market Attractiveness Analysis By End-user
   16.22 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
      16.22.1 Hospital Pharmacies
      16.22.2 Retail Pharmacies
      16.22.3 Online Pharmacies
   16.23 Basis Point Share (BPS) Analysis By Distribution Channel
   16.24 Absolute $ Opportunity Assessment By Distribution Channel
   16.25 Market Attractiveness Analysis By Distribution Channel
Chapter 17 Competition Landscape
   17.1 Intranasal Drug Delivery Devices Market: Competitive Dashboard
   17.2 Global Intranasal Drug Delivery Devices Market: Market Share Analysis, 2020
   17.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      17.3.1 3M
      17.3.2 AptarGroup, Inc.
      17.3.3 BD
      17.3.4 Eli Lilly and Company
      17.3.5 GSK group
      17.3.6 Heitkamp & Thumann Group
      17.3.7 Johnson & Johnson Services, Inc
      17.3.8 Nemera
      17.3.9 Neurelis, Inc.
      17.3.10 Recipharm AB (Bespak)
      17.3.11 Teleflex Incorporated
      17.3.12 Vectura Group plc

Purchase Premium Report

FAQ Section

Some frequently asked questions about this report!

Major Manufacturers Johnson & Johnson, BD, Teva Pharmaceutical Industries Ltd, Nemera Development S.A., AptarGroup, Inc., and Recipharm AB Limited.

Factors such as Product Launch, Government Initiatives & Regulations, GDP, and Healthcare Industry are expected to act as a driving force for the market.

The base year considered for the global Intranasal Drug Delivery Devices market report is 2020. The complete analysis period is 2018 to 2028, wherein, 2018, and 2019 are the historic years, and the forecast is provided from 2021 to 2028.

The market is expected to witness a significant increase in growth between 2019 and 2020 owing to the COVID 19 pandemic in the Intranasal Drug Delivery Devices market.

The major applications of Intranasal Drug Delivery Devices are Respiratory Disorders, Neurological Disorder, Vaccination, Pain Management, and Others.

Increasing prevalence of chronic diseases, increasing focus on alternative routes such as nasal drug delivery, and increasing awareness about intranasal drug delivery devices expected to act as a driving force for the market during forecast period.

Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.

In addition to market size (in US$ Million), Company Market Share (in % for base year 2019), and quality parameter overview is provided.

According to this Growth Market Reports, the intranasal drug delivery devices market is likely to register a CAGR of 6.5% during forecast period 2020-2027, with an anticipated valuation of USD 6,601.7 Mn by the end of the 2028.

Additional company profiles can be provided on request